New AI tool can predict liver cancer with 82% accuracy – free online web portal available Singapore scientists have developed an AI tool that predicts liver cancer relapse with 82 per cent accuracy.

Northwestern Print replaced NUPrint in late June as part of the Procurement and Payment Services department’s effort to reduce costs and unify printing services across NU’s Evanston and ...

A lightning strike late Tuesday evening sparked a devastating house fire near Mt. Lemmon, destroying a longtime resident's home and leaving him with a little more than the clothes on his back.

Joel has experience working with web, print and video in the tech, finance, nonprofit and the public sectors. In his off-time, you might catch Joel taking part in Tucson's local comedy scene.

Harvard researchers say money will soon run out to cover the costs of preserving the samples collected over decades from roughly 350,000 people.

Disturbing and salacious details continue to emerge about the lavish spending of Albert II, the ruler of the tiny Mediterranean principality that is a playground for the world’s super rich.

Operation Spider’s Web has left a ripple effect that is still being felt in the aftermath of the attack. Here is why these drone strikes were so remarkable, and how they could affect the future ...

Women receiving endocrine therapy for hormone receptor (HR)–positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking ...

The Oregon Ducks bolstered their running back room this offseason with the transfer portal addition of Makhi Hughes. He's expected to form a lethal one-two punch with starting running back Noah ...

Understanding portal hypertension symptoms, causes & complications including varices, ascites, and hepatic encephalopathy.

Congressional Democrats, including U.S. Rep. Debbie Wasserman Schultz, D-Weston, have created a portal website to field complaints from constituents who believe they have been hurt by the policies ...

In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease ...